Beam Therapeutics (BEAM) Projected to Post Quarterly Earnings on Tuesday

Key Points

• Beam Therapeutics (NASDAQ:BEAM) is set to announce its Q2 2025 earnings on August 5th, with analysts expecting a loss of ($1.04) per share and revenue of $13.29 million.
• In its previous earnings report on May 6th, the company reported a loss of ($1.24) per share and a revenue of $7.47 million, missing expectations.
• Institutional investors, including Jones Financial Companies, have significantly increased their positions in Beam, now holding 99.68% of the stock.

Beam Therapeutics (NASDAQ:BEAM - Get Free Report) is expected to be issuing its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 5th. Analysts expect the company to announce earnings of ($1.04) per share and revenue of $13.29 million for the quarter.

Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($1.24) EPS for the quarter, missing analysts' consensus estimates of ($1.11) by ($0.13). The business had revenue of $7.47 million for the quarter, compared to analysts' expectations of $14.69 million. Beam Therapeutics had a negative net margin of 609.24% and a negative return on equity of 44.24%. The company's revenue for the quarter was up 1.4% on a year-over-year basis. During the same period last year, the business posted ($1.21) EPS. On average, analysts expect Beam Therapeutics to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Beam Therapeutics Price Performance

NASDAQ BEAM traded down $0.91 during trading on Friday, reaching $18.81. 2,044,024 shares of the company's stock traded hands, compared to its average volume of 2,043,286. The firm has a market cap of $1.89 billion, a price-to-earnings ratio of -4.10 and a beta of 2.07. The company's 50 day simple moving average is $18.63 and its two-hundred day simple moving average is $21.23. Beam Therapeutics has a 12-month low of $13.52 and a 12-month high of $35.25.

Insider Buying and Selling

In related news, insider Fmr Llc sold 48,374 shares of Beam Therapeutics stock in a transaction that occurred on Wednesday, July 30th. The shares were sold at an average price of $20.50, for a total value of $991,667.00. Following the completion of the sale, the insider directly owned 2,073,665 shares in the company, valued at $42,510,132.50. This trade represents a 2.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last ninety days, insiders have sold 49,624 shares of company stock valued at $1,015,628. 3.50% of the stock is owned by company insiders.

Institutional Trading of Beam Therapeutics

A hedge fund recently raised its stake in Beam Therapeutics stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 10.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 438,529 shares of the company's stock after acquiring an additional 42,609 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned approximately 0.44% of Beam Therapeutics worth $8,564,000 at the end of the most recent quarter. Institutional investors own 99.68% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on BEAM. Guggenheim cut their target price on shares of Beam Therapeutics from $78.00 to $55.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Wells Fargo & Company lowered their price target on shares of Beam Therapeutics from $75.00 to $70.00 and set an "overweight" rating on the stock in a report on Wednesday, May 7th. HC Wainwright restated a "buy" rating and issued a $80.00 price target on shares of Beam Therapeutics in a report on Monday, April 7th. Barclays lowered their price target on shares of Beam Therapeutics from $31.00 to $25.00 and set an "equal weight" rating on the stock in a report on Wednesday, May 7th. Finally, Cantor Fitzgerald upgraded shares of Beam Therapeutics to a "strong-buy" rating in a report on Monday, July 21st. Two analysts have rated the stock with a hold rating, ten have assigned a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, Beam Therapeutics presently has a consensus rating of "Buy" and an average price target of $48.75.

About Beam Therapeutics

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.